Company: CERO
Filing Date: 2025-07-25
Form Type: 424B3
Source: 0001213900-25-067733
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-25
Form: 424B3
Chunk 2
---
 the Exchange Act (17 CFR 240.13e-4(c)) |

<div align='center'>Securities registered pursuant to Section 12(b) of the Act:</div>

| Title of each class                                                                  |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, $0.0001 par value per share                                            |     | CERO              |     | Nasdaq                                    
 Capital Market                            |
| Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock |     | CEROW             |     | Nasdaq                                    
 Capital Market                            |

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 3.02 Unregistered Sales of Equity Securities.

As previously reported on the Current Report on
Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 22, 2025 and June 30, 2025, CERo Therapeutics
Holdings, Inc. (the “Company”) entered into the Securities Purchase Agreement on April 21, 2025, as amended by that certain
Amendment No. 1 to the Securities Purchase Agreement on June 25, 2025 (collectively, the “Securities Purchase Agreement”)
with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in one or
more closings, up to 10,000 shares of the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series
D Preferred Stock”), which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”), in a private placement offering. As previously reported on the Current Report on Form 8-K filed with the SEC on June 6,
2025 and on June 30, 2025, the Company completed Additional